Engineering of Escherichia coli strains for plasmid biopharmaceutical production: Scale-up challenges
Plasmid-based vaccines and therapeutics have been making their way into the clinic in the last years. The existence of cost-effective manufacturing processes capable of delivering high amounts of high-quality plasmid DNA (pDNA) is essential to generate enough material for trials and support future c...
| Main Authors: | , , , |
|---|---|
| Other Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
Elsevier,
2016-02-23T20:12:59Z.
|
| Subjects: | |
| Online Access: | Get fulltext |